Pub Date : 2025-01-01DOI: 10.1016/j.artere.2025.100723
Kung-Hung Lin , Nuria Amigo , Pablo Ortiz , Cristina Alonso , Alexander V. Smolensky , Deven Parmar , Naga P. Chalasani , Samer Gawrieh
Background and aims
Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease (CVD) is challenging due to interactions among a large number of parameters that modulate CVD risk.
Methods
We developed an illustrative tool, athero-contour (AC), which incorporates weighted key lipid, lipo- and glycoprotein parameters, to readily illustrate their overall changes following pharmacotherapy. We demonstrate the applicability of AC to assess changes in AP in response to saroglitazar treatment in patients with metabolic associated fatty liver disease (MAFLD) in the EVIDENCES IV study.
Results
The baseline AC of saroglitazar and placebo groups was worse than the mean of the general population. After 16-week treatment, AC improved significantly in the saroglitazar group due to alterations in very low-density lipoprotein, triglyceride, and glycoproteins.
Conclusion
Using AC, we could readily and globally evaluate and visualize changes in AP. AC improved in patients with MAFLD following saroglitazar therapy.
{"title":"The athero-contour: A novel tool for global and rapid assessment of atherogenic parameters. A use case in saroglitazar treatment of MAFLD patients","authors":"Kung-Hung Lin , Nuria Amigo , Pablo Ortiz , Cristina Alonso , Alexander V. Smolensky , Deven Parmar , Naga P. Chalasani , Samer Gawrieh","doi":"10.1016/j.artere.2025.100723","DOIUrl":"10.1016/j.artere.2025.100723","url":null,"abstract":"<div><h3>Background and aims</h3><div>Comprehensive assessment of pharmacotherapy effects on atherogenic parameters (AP) that influence the risk of cardiovascular disease (CVD) is challenging due to interactions among a large number of parameters that modulate CVD risk.</div></div><div><h3>Methods</h3><div>We developed an illustrative tool, athero-contour (AC), which incorporates weighted key lipid, lipo- and glycoprotein parameters, to readily illustrate their overall changes following pharmacotherapy. We demonstrate the applicability of AC to assess changes in AP in response to saroglitazar treatment in patients with metabolic associated fatty liver disease (MAFLD) in the EVIDENCES IV study.</div></div><div><h3>Results</h3><div>The baseline AC of saroglitazar and placebo groups was worse than the mean of the general population. After 16-week treatment, AC improved significantly in the saroglitazar group due to alterations in very low-density lipoprotein, triglyceride, and glycoproteins.</div></div><div><h3>Conclusion</h3><div>Using AC, we could readily and globally evaluate and visualize changes in AP. AC improved in patients with MAFLD following saroglitazar therapy.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 100723"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.artere.2025.500764
Francisco Pérez-Jiménez
{"title":"Nutritional recommendations: an easy and difficult task for the doctor","authors":"Francisco Pérez-Jiménez","doi":"10.1016/j.artere.2025.500764","DOIUrl":"10.1016/j.artere.2025.500764","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 500764"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.artere.2025.100732
Francesco Sbrana, Beatrice Dal Pino
{"title":"When “old” lipid lowering therapies not should be discontinued","authors":"Francesco Sbrana, Beatrice Dal Pino","doi":"10.1016/j.artere.2025.100732","DOIUrl":"10.1016/j.artere.2025.100732","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 100732"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.artere.2025.100724
Vicente Pallarés-Carratalá , Antonio Ruiz-García , Adalberto Serrano-Cumplido , Antonio Segura Fragoso , Verónica Fernández-Pascual , Beatriz Sánchez-Sánchez , María Inmaculada Cervera-Pérez , Francisco Javier Alonso-Moreno , Ezequiel Arranz-Martínez , Alfonso Barquilla-García , Daniel Rey-Aldana , José Polo García , Sergio Cinza-Sanjurjo , on behalf of the Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation
Introduction
Type 2 diabetes mellitus (T2D) has acquired epidemic proportions worldwide. In recent years, new oral glucose-lowering drugs (OGLD) have emerged that improve the cardiovascular–kidney–metabolic control in T2D people.
Objectives
To compare the baseline clinical–biological characteristics among T2D people to whom had added-on dapagliflozin (DAPA group) or another OGLD (SOC group) second-line hypoglycaemic therapies among the AGORA study population.
Methods
This is a multicentre cross-sectional observational study of the baseline characteristics of T2D people recruited through competitive sampling among 46 primary care health centres in Spain for the AGORA study. The inclusion and exclusion criteria of participants, and justification of the sample size are reported. After verifying the data necessary to be evaluated and informed consent, 317 subjects were included to the DAPA group and 288 to the SOC group. Both categorical and continuous variables were analysed and compared with the usual statistics. Cohen's d was used to assess the standardised difference in means.
Results
Six hundred and five patients with T2D were assessed (mean age 63.5 [SD ± 8.1] years, 61.8% men), whom 17.4% were smokers, 47.6% had obesity, 74.8% hypertension, 87.3% dyslipidaemia, and 41.7% reported physical inactivity, with no significant differences between both comparison groups. The mean (SD) evolution time of T2D was 10.1 (5.6) years. Most baseline clinical–biological characteristics at recruitment were similar in both groups. However, DAPA group was younger (2.9 years), and had lower systolic blood pressure (SBP) (2.8 mmHg), higher body weight (BW) (3.7 kg), and higher glycated haemoglobin A1c (HbA1c) (0.3%) than SOC group. Only 11.5% of participants had poor glycaemic control (HbA1c > 8%) at recruitment, 54.9% had good glycaemic control (HbA1c < 7%), being significantly lower in the DAPA group (47.3%) than in the SOC group (63.4%). The percentage of T2D patients with high vascular risk (VR) was 46.3%, and 53.7% with very high VR, being significantly higher in the DAPA group (57.4%) than in the SOC group (49.6%).
Conclusions
Most baseline cardiovascular–kidney–metabolic characteristics were similar in T2D patients whom had added dapagliflozin on second-line hypoglycaemic therapy as those whom had added-on another OGLD. However, patients whom had added-on dapagliflozin had higher VR, lower SBP, higher BW, and slightly worse HbA1c control. Future research is necessary to explain the causes of these differences in cardiometabolic control.
{"title":"Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study","authors":"Vicente Pallarés-Carratalá , Antonio Ruiz-García , Adalberto Serrano-Cumplido , Antonio Segura Fragoso , Verónica Fernández-Pascual , Beatriz Sánchez-Sánchez , María Inmaculada Cervera-Pérez , Francisco Javier Alonso-Moreno , Ezequiel Arranz-Martínez , Alfonso Barquilla-García , Daniel Rey-Aldana , José Polo García , Sergio Cinza-Sanjurjo , on behalf of the Investigators of the AGORA study, of the Spanish Society of Primary Care Physicians SEMERGEN Foundation","doi":"10.1016/j.artere.2025.100724","DOIUrl":"10.1016/j.artere.2025.100724","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 2 diabetes mellitus (T2D) has acquired epidemic proportions worldwide. In recent years, new oral glucose-lowering drugs (OGLD) have emerged that improve the cardiovascular–kidney–metabolic control in T2D people.</div></div><div><h3>Objectives</h3><div>To compare the baseline clinical–biological characteristics among T2D people to whom had added-on dapagliflozin (DAPA group) or another OGLD (SOC group) second-line hypoglycaemic therapies among the AGORA study population.</div></div><div><h3>Methods</h3><div>This is a multicentre cross-sectional observational study of the baseline characteristics of T2D people recruited through competitive sampling among 46 primary care health centres in Spain for the AGORA study. The inclusion and exclusion criteria of participants, and justification of the sample size are reported. After verifying the data necessary to be evaluated and informed consent, 317 subjects were included to the DAPA group and 288 to the SOC group. Both categorical and continuous variables were analysed and compared with the usual statistics. Cohen's <em>d</em> was used to assess the standardised difference in means.</div></div><div><h3>Results</h3><div>Six hundred and five patients with T2D were assessed (mean age 63.5 [SD<!--> <!-->±<!--> <!-->8.1] years, 61.8% men), whom 17.4% were smokers, 47.6% had obesity, 74.8% hypertension, 87.3% dyslipidaemia, and 41.7% reported physical inactivity, with no significant differences between both comparison groups. The mean (SD) evolution time of T2D was 10.1 (5.6) years. Most baseline clinical–biological characteristics at recruitment were similar in both groups. However, DAPA group was younger (2.9 years), and had lower systolic blood pressure (SBP) (2.8<!--> <!-->mmHg), higher body weight (BW) (3.7<!--> <!-->kg), and higher glycated haemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) (0.3%) than SOC group. Only 11.5% of participants had poor glycaemic control (HbA<sub>1c</sub> <!-->><!--> <!-->8%) at recruitment, 54.9% had good glycaemic control (HbA<sub>1c</sub> <!--><<!--> <!-->7%), being significantly lower in the DAPA group (47.3%) than in the SOC group (63.4%). The percentage of T2D patients with high vascular risk (VR) was 46.3%, and 53.7% with very high VR, being significantly higher in the DAPA group (57.4%) than in the SOC group (49.6%).</div></div><div><h3>Conclusions</h3><div>Most baseline cardiovascular–kidney–metabolic characteristics were similar in T2D patients whom had added dapagliflozin on second-line hypoglycaemic therapy as those whom had added-on another OGLD. However, patients whom had added-on dapagliflozin had higher VR, lower SBP, higher BW, and slightly worse HbA<sub>1c</sub> control. Future research is necessary to explain the causes of these differences in cardiometabolic control.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 100724"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.artere.2025.100742
Javier Rodríguez Lega, Ángel González Pinto
{"title":"Assessment of the impact on thrombogenicity of surface modifications on nitinol stents in an in vitro model","authors":"Javier Rodríguez Lega, Ángel González Pinto","doi":"10.1016/j.artere.2025.100742","DOIUrl":"10.1016/j.artere.2025.100742","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 100742"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.artere.2025.100721
Oscar Zaragoza-García , Olivia Briceño , José Rafael Villafan-Bernal , Ilse Adriana Gutiérrez-Pérez , Héctor Ugo Rojas-Delgado , Gustavo Adolfo Alonso-Silverio , Antonio Alarcón-Paredes , José Eduardo Navarro-Zarza , Cristina Morales-Martínez , Rubén Rodríguez-García , Iris Paola Guzmán-Guzmán
Aim
The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).
Methods
A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163 were determined by the ELISA method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.
Results
Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR) ≥ 0.121 (p = 0.003), total cholesterol/HDL-c ratio > 7% (p = 0.004), LDL-c/HDL-c ratio > 3% (p = 0.035), atherogenic index of plasma > 0.21 (p = 0.004), cardiometabolic index (CMI) ≥ 1.70 (p = 0.005), and high DAS28-ESR (p = 0.004). In multivariate analysis, levels of sCD163 ≥ 1107.3 ng/mL were associated with CHR ≥ 0.121 (OR = 3.43, p = 0.020), CMI ≥ 1.70 (OR = 4.25, p = 0.005), total cholesterol/HDL-c ratio > 7% (OR = 6.63, p = 0.044), as well as with DAS28-ESR > 3.2 (OR = 8.10, p = 0.008). Moreover, levels of sCD163 predicted CHR ≥ 0.121 (AUC = 0.701), cholesterol total/HDL ratio > 7% (AUC = 0.764), and DAS28-ESR > 3.2 (AUC = 0.720).
Conclusion
Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.
{"title":"Levels of sCD163 in women rheumatoid arthritis: Relationship with cardiovascular risk markers","authors":"Oscar Zaragoza-García , Olivia Briceño , José Rafael Villafan-Bernal , Ilse Adriana Gutiérrez-Pérez , Héctor Ugo Rojas-Delgado , Gustavo Adolfo Alonso-Silverio , Antonio Alarcón-Paredes , José Eduardo Navarro-Zarza , Cristina Morales-Martínez , Rubén Rodríguez-García , Iris Paola Guzmán-Guzmán","doi":"10.1016/j.artere.2025.100721","DOIUrl":"10.1016/j.artere.2025.100721","url":null,"abstract":"<div><h3>Aim</h3><div>The soluble scavenger receptor differentiation antigen 163 (sCD163), a monocyte/macrophage activation marker, is related to cardiovascular mortality in the general population. This study aimed to evaluate their relationship between serum levels of sCD163 with cardiovascular risk indicators in rheumatoid arthritis (RA).</div></div><div><h3>Methods</h3><div>A cross-sectional study was performed on 80 women diagnosed with RA. The cardiovascular risks were determined using the lipid profile, metabolic syndrome, and QRISK3 calculator. For the assessment of RA activity, we evaluated the DAS28 with erythrocyte sedimentation rate (DAS28-ESR). The serum levels of sCD163 were determined by the ELISA method. Logistic regression models and receiver operating characteristics (ROC) curve were used to assess the association and predictive value of sCD163 with cardiovascular risk in RA patients.</div></div><div><h3>Results</h3><div>Levels of sCD163 were significantly higher in RA patients with high sensitivity protein C-reactive to HDL-c ratio (CHR)<!--> <!-->≥<!--> <!-->0.121 (<em>p</em> <!-->=<!--> <!-->0.003), total cholesterol/HDL-c ratio<!--> <!-->><!--> <!-->7% (<em>p</em> <!-->=<!--> <!-->0.004), LDL-c/HDL-c ratio<!--> <!-->><!--> <!-->3% (<em>p</em> <!-->=<!--> <!-->0.035), atherogenic index of plasma<!--> <!-->><!--> <!-->0.21 (<em>p</em> <!-->=<!--> <!-->0.004), cardiometabolic index (CMI)<!--> <!-->≥<!--> <!-->1.70 (<em>p</em> <!-->=<!--> <!-->0.005), and high DAS28-ESR (<em>p</em> <!-->=<!--> <!-->0.004). In multivariate analysis, levels of sCD163<!--> <!-->≥<!--> <!-->1107.3<!--> <!-->ng/mL were associated with CHR<!--> <!-->≥<!--> <!-->0.121 (OR<!--> <!-->=<!--> <!-->3.43, <em>p</em> <!-->=<!--> <!-->0.020), CMI<!--> <!-->≥<!--> <!-->1.70 (OR<!--> <!-->=<!--> <!-->4.25, <em>p</em> <!-->=<!--> <!-->0.005), total cholesterol/HDL-c ratio<!--> <!-->><!--> <!-->7% (OR<!--> <!-->=<!--> <!-->6.63, <em>p</em> <!-->=<!--> <!-->0.044), as well as with DAS28-ESR<!--> <!-->><!--> <!-->3.2 (OR<!--> <!-->=<!--> <!-->8.10, <em>p</em> <!-->=<!--> <!-->0.008). Moreover, levels of sCD163 predicted CHR<!--> <!-->≥<!--> <!-->0.121 (AUC<!--> <!-->=<!--> <!-->0.701), cholesterol total/HDL ratio<!--> <!-->><!--> <!-->7% (AUC<!--> <!-->=<!--> <!-->0.764), and DAS28-ESR<!--> <!-->><!--> <!-->3.2 (AUC<!--> <!-->=<!--> <!-->0.720).</div></div><div><h3>Conclusion</h3><div>Serum levels of sCD163 could be considered a surrogate of cardiovascular risk and clinical activity in RA.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"37 1","pages":"Article 100721"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To understand the prevalence of subclinical atherosclerosis (SCA) in psoriatic arthritis (PsA) patients; to explore the correlation between PsA combined with SCA and traditional cardiovascular risk factors and disease activity; to compare the role of Framingham Risk Score (FRS) and atherosclerotic cardiovascular disease (ASCVD) scores.
Methods
We included 50 PsA patients who met the CASPAR classification criteria, 50 diabetes patients and 50 healthy people. Clinical data were collected from all patients, minimal disease activity (MDA), disease activity index for psoriatic arthritis (DAPSA), ASCVD, FRS were assessed in patients with PsA, and carotid artery intima–media thickness was measured.
Results
The prevalence of SCA in PsA patients was significantly higher than that in healthy controls (44% vs 24%, P < 0.05). Smoking, drinking, ASCVD, FRS were the risk factors of PsA with SCA (P < 0.05). Psoriasis (PsO) duration, PtGA, VAS and DAPSA were the risk factors for PsA with SCA (P < 0.05). FRS and ASCVD scores underestimated SCA risk in PsA patients.
Conclusion
Compared with healthy controls, patients with PsA have higher prevalence of SCA. High DAPSA is a risk factor for PsA with SCA. Carotid ultrasound can monitor SCA in patients with PsA, improve stratification of cardiovascular risk.
{"title":"Risk factors and assessment of subclinical atherosclerosis in patients with psoriatic arthritis","authors":"Zhoulan Zheng , Qianru Liu , Zhenan Zhang , Qianyu Guo , Liyun Zhang , Gailian Zhang","doi":"10.1016/j.artere.2024.11.002","DOIUrl":"10.1016/j.artere.2024.11.002","url":null,"abstract":"<div><h3>Objective</h3><div>To understand the prevalence of subclinical atherosclerosis (SCA) in psoriatic arthritis (PsA) patients; to explore the correlation between PsA combined with SCA and traditional cardiovascular risk factors and disease activity; to compare the role of Framingham Risk Score (FRS) and atherosclerotic cardiovascular disease (ASCVD) scores.</div></div><div><h3>Methods</h3><div>We included 50 PsA patients who met the CASPAR classification criteria, 50 diabetes patients and 50 healthy people. Clinical data were collected from all patients, minimal disease activity (MDA), disease activity index for psoriatic arthritis (DAPSA), ASCVD, FRS were assessed in patients with PsA, and carotid artery intima–media thickness was measured.</div></div><div><h3>Results</h3><div>The prevalence of SCA in PsA patients was significantly higher than that in healthy controls (44% vs 24%, <em>P</em> <!--><<!--> <!-->0.05). Smoking, drinking, ASCVD, FRS were the risk factors of PsA with SCA (<em>P</em> <!--><<!--> <!-->0.05). Psoriasis (PsO) duration, PtGA, VAS and DAPSA were the risk factors for PsA with SCA (<em>P</em> <!--><<!--> <!-->0.05). FRS and ASCVD scores underestimated SCA risk in PsA patients.</div></div><div><h3>Conclusion</h3><div>Compared with healthy controls, patients with PsA have higher prevalence of SCA. High DAPSA is a risk factor for PsA with SCA. Carotid ultrasound can monitor SCA in patients with PsA, improve stratification of cardiovascular risk.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 6","pages":"Pages 333-340"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.artere.2024.10.003
José Luis Sánchez-Quesada
{"title":"A new perspective on the regulatory role of miRNAS. Cross-kingdom regulation","authors":"José Luis Sánchez-Quesada","doi":"10.1016/j.artere.2024.10.003","DOIUrl":"10.1016/j.artere.2024.10.003","url":null,"abstract":"","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 6","pages":"Pages 341-342"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.artere.2024.11.001
María del Carmen López de las Hazas , Joao Tomé-Carneiro , Livia Balaguer , Gema de la Peña , Luis A. Chapado , Marta Alonso-Bernáldez , Andrea del Saz-Lara , Judit Gil-Zamorano , Emma Burgos-Ramos , María Rodríguez-Pérez , Diego Gómez-Coronado , Alberto Dávalos
Aim
Epidemiological evidence suggests adherence to vegetable-rich diets is associated to atheroprotective effects and bioactive components are most likely to play a relevant role. The notion of inter-kingdom regulation has opened a new research paradigm and perhaps microRNAs (miRNAs) from edible vegetables could influence consumer gene expression and lead to biological effects. We aimed to investigate the potential impact of broccoli-derived miRNAs on cellular cholesterol efflux in vitro.
Methods
Four miRNAs (miR159a, miR159b, miR166a and miR403) from Brassica oleracea var. italica (broccoli), a widely consumed cruciferous vegetable, were selected for further investigation, based on their high abundancy in this vegetable and their presence in other plants. Selected miRNAs were synthesized with a 3′-terminal 2′-O-methylation and their cellular toxicity, in vitro gastrointestinal resistance and cellular uptake were evaluated. Potential target genes within the mammalian transcriptome were assessed in silico following pathway analysis. In vitro cholesterol efflux was assessed in human THP-1-derived macrophages.
Results
miRNAs survival to in vitro GI digestion was around 1%, although some variation was seen between the four candidates. Cellular uptake by mammalian cells was confirmed, and an increase in cholesterol efflux was observed. Pathway analysis suggested these miRNAs are involved in biological processes related to phosphorylation, phosphatidylinositol and Wnt signaling, and to the insulin/IGF pathway.
Conclusions
Health-promoting properties attributed to cruciferous vegetables, might be mediated (at least in part) through miRNA-related mechanisms.
{"title":"Dietary plant microRNAs as potential regulators of cellular cholesterol efflux","authors":"María del Carmen López de las Hazas , Joao Tomé-Carneiro , Livia Balaguer , Gema de la Peña , Luis A. Chapado , Marta Alonso-Bernáldez , Andrea del Saz-Lara , Judit Gil-Zamorano , Emma Burgos-Ramos , María Rodríguez-Pérez , Diego Gómez-Coronado , Alberto Dávalos","doi":"10.1016/j.artere.2024.11.001","DOIUrl":"10.1016/j.artere.2024.11.001","url":null,"abstract":"<div><h3>Aim</h3><div>Epidemiological evidence suggests adherence to vegetable-rich diets is associated to atheroprotective effects and bioactive components are most likely to play a relevant role. The notion of inter-kingdom regulation has opened a new research paradigm and perhaps microRNAs (miRNAs) from edible vegetables could influence consumer gene expression and lead to biological effects. We aimed to investigate the potential impact of broccoli-derived miRNAs on cellular cholesterol efflux in vitro.</div></div><div><h3>Methods</h3><div>Four miRNAs (miR159a, miR159b, miR166a and miR403) from <em>Brassica oleracea</em> var. <em>italica</em> (broccoli), a widely consumed cruciferous vegetable, were selected for further investigation, based on their high abundancy in this vegetable and their presence in other plants. Selected miRNAs were synthesized with a 3′-terminal 2′-O-methylation and their cellular toxicity, in vitro gastrointestinal resistance and cellular uptake were evaluated. Potential target genes within the mammalian transcriptome were assessed in silico following pathway analysis. In vitro cholesterol efflux was assessed in human THP-1-derived macrophages.</div></div><div><h3>Results</h3><div>miRNAs survival to in vitro GI digestion was around 1%, although some variation was seen between the four candidates. Cellular uptake by mammalian cells was confirmed, and an increase in cholesterol efflux was observed. Pathway analysis suggested these miRNAs are involved in biological processes related to phosphorylation, phosphatidylinositol and Wnt signaling, and to the insulin/IGF pathway.</div></div><div><h3>Conclusions</h3><div>Health-promoting properties attributed to cruciferous vegetables, might be mediated (at least in part) through miRNA-related mechanisms.</div></div>","PeriodicalId":100263,"journal":{"name":"Clínica e Investigación en Arteriosclerosis (English Edition)","volume":"36 6","pages":"Pages 315-324"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142705850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号